A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK(+) lymphomas

Detalles Bibliográficos
Autores principales: Rindone, Giovanni, Aroldi, Andrea, Bossi, Elisa, Verga, Luisa, Zambrotta, Giovanni, Tarantino, Sara, Piazza, Rocco, Mussolin, Lara, Chiarle, Roberto, Gambacorti-Passerini, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898594/
https://www.ncbi.nlm.nih.gov/pubmed/35914224
http://dx.doi.org/10.1182/bloodadvances.2022007538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898594/
https://www.ncbi.nlm.nih.gov/pubmed/35914224
http://dx.doi.org/10.1182/bloodadvances.2022007538

Ejemplares similares